• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Summit lung cancer drug shows ‘striking’ benefit over Keytruda

cafead

Administrator
Staff member
  • cafead   Sep 08, 2024 at 11:42: PM
via An experimental medicine from a small biotechnology company cut the risk of lung cancer progression in half when tested against the world’s most dominant immunotherapy in a clinical trial, according to study data presented Sunday at a major medical meeting.

article source